Form 4: Immuneering Corp. Director Peter Feinberg Granted 33,350 Stock Options

Immuneering Corp. Director Peter Feinberg was granted 33,350 stock options with an exercise price of $1.90, vesting over a one-year period.

Summary

• Peter Feinberg, a Director of Immuneering Corp. (IMRX), was granted 33,350 stock options.
• The transaction date for this grant was June 13, 2025.
• The exercise price for these stock options is $1.90 per share.
• The options will vest in equal monthly installments over a one-year period, commencing on July 13, 2025.
• The options will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever occurs first.
• The expiration date for these stock options is June 13, 2035.
• Following this transaction, Peter Feinberg beneficially owns 33,350 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it represents a potential future dilution, it is a standard compensation practice that aligns the director's interests with the company's long-term performance, which is generally viewed favorably.

Positives

• The grant of stock options aligns the financial interests of Director Peter Feinberg with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, indicating continued engagement and commitment from key personnel.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shares, although this is a common aspect of equity compensation plans.

Future Outlook

The stock options granted to Director Peter Feinberg are set to vest in equal monthly installments over a one-year period, commencing July 13, 2025, and will be fully vested by June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first. This outlines a clear future timeline for the director's equity compensation.

Industry Context

This Form 4 filing represents a routine insider transaction, specifically the grant of stock options as part of a director's compensation package. Such grants are common practice across the biotechnology and pharmaceutical industries, aiming to align the interests of company leadership with long-term shareholder value creation.

Related Party Transactions

• The grant of stock options to Peter Feinberg, a Director of Immuneering Corp., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from increased alignment of the director's interests with long-term share price appreciation.
• Director (Peter Feinberg): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will begin vesting in equal monthly installments starting July 13, 2025.
• The options will continue to vest until fully exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever is earlier.
• Peter Feinberg may choose to exercise these options at any point after they vest and before their expiration date of June 13, 2035.

Key Dates

Keywords

Immuneering Corp, IMRX, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule